Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADIL with… →

ADIL Key Statistics

As of Sep 4, 2026

Trading

Open: $6.61
Previous Close: $6.66
Day's Range: 6.27–7.20
52-Week Range: 1.31–10.75
Volume: 50.10K
Beta: 1.39

Valuation

Market Cap: $20.89M
P/E Ratio: unprofitable
EPS (ttm): −18.63

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$7.98M
Profit margin: 0.00%
Shares Outstanding: 2.93M
1-Year Return: −18.63%

Dividend and dates

Avg Volume: 420.59K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ADIL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+58.82%−91.85%+29.45%

2018*20192020202120222023202420252026*

Year	Return
2026 (partial year)	+29.45%
2025	−78.22%
2024	−45.70%
2023	−66.18%
2022	−91.85%
2021	+58.82%
2020	−29.46%
2019	−52.93%
2018 (partial year)	+26.42%

As of September 4, 2026.

ADIL Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$7.98M	—
2024	$0.00	−$13.20M	—
2023	$0.00	−$5.12M	—
2022	$0.00	−$12.73M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$7.80M	−$7.98M	—
2024	$0.00	—	−$8.28M	−$13.20M	—
2023	$0.00	—	−$6.89M	−$5.12M	—
2022	$0.00	—	−$10.86M	−$12.73M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADIL Valuation vs Biotechnology Median

Median of 656 stocks

Metric	ADIL	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Adial Pharmaceuticals, Inc. (ADIL) at $20.89M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 5.

Over the past 52 weeks the price has ranged from $1.31 to $10.75. The most recent close on file for ADIL is $7.12, dated September 4, 2026. That is +$0.46 (+6.91%) against the previous close. The latest close sits 443.51% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $7.98M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −18.63.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.39. Daily returns over the trailing 8 years annualize to a volatility of 141.9%. The trailing one-year price return is −18.63%. Across 5 years the annualized return works out at −69.55%.

Growth & Income

The record shows no dividend for ADIL.

So far in 2026 the price is +29.45%. The strongest complete calendar year on file is 2021 at +58.82%; the weakest is 2022 at −91.85%. Of the 7 complete calendar years on file, 1 finished higher.

Peer Comparison

Adial Pharmaceuticals, Inc. (ADIL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Adial Pharmaceuticals, Inc.	ADIL	$20.89M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Adial Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Visit website →

Adial Pharmaceuticals, Inc. (ADIL) Stock Analysis